this is old published phase I study before Prima acquired Immutep ,would have been nice to see longer term follow up of theses patients, and was not progressed to Phase II
main reason for sharing is to remind the potential in other products
A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
this was conclusion of authors
Conclusion: The absence of toxicity and the demonstration of activity at doses above 6 mg warrant further disease-directed studies of IMP321 in combined regimens (e.g., chemoimmunotherapy). (Clin Cancer Res 2009;15(19):6225–31)
http://clincancerres.aacrjournals.org/content/15/19/6225.long
IMP 321
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
0.010(2.30%) |
Mkt cap ! $517.1M | |||
| Open | High | Low | Value | Volume |
| 44.5¢ | 44.5¢ | 44.5¢ | $45.37K | 101.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 229608 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 322312 | 12 |
View Market Depth
| Last trade - 10.04am 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
46.0¢ |
Change
0.010 ( 5.75 %) |
||||
| Open | High | Low | Volume | ||
| 45.0¢ | 46.5¢ | 45.0¢ | 140505 | ||
| Last updated 10.23am 06/05/2024 ? | |||||
| IMM (ASX) Chart |